查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2053323

全球分子診斷市場—機會與成長指標

Global Molecular Diagnostic Market - Opportunities and Growth Indicators
出版日期: | 出版商: Frost & Sullivan | 英文 51 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

分子診斷產業正在經歷重組，需要加快資本投資和監管核准流程，以加速臨床應用。領先的診斷和生命科學公司正在收購專有檢測平台，以鞏固其在精準腫瘤學和血液學診斷領域的地位。人工智慧驅動的基因組分析工作流程系統正成為關鍵的競爭優勢，能夠實現大規模基因組分析，並改善常規實踐中先進診斷技術的可近性。數位PCR (dPCR)、新一代定序 (NGS)、CRISPR-Cas 和奈米技術的融合正在建立一個多平台分子檢測生態系統，在癌症、感染疾病和精準醫療領域顯著提升檢測速度、準確性和擴充性。 NGS 透過在腫瘤學、罕見疾病和生殖醫學領域快速且經濟高效的多基因分析，持續推動檢測技術的應用，而像 MGI Tech 這樣的公司則透過自動化定序解決方案擴大了檢測範圍。此外，該產業的併購也不斷增加，其驅動力在於拓展產品組合、加強研發和加速商業化。同時，人工智慧正逐漸成為檢查室的“副駕駛”，透過與實驗室資訊管理系統（LIMS）和“人機協同”臨床檢驗框架的整合，提高操作效率和診斷準確性。伴隨診斷正成為精準醫療的核心，賽默飛世爾科技與輝瑞、Guardant Health與輝瑞以及Illumina與製藥公司之間的合作，正在推動基於檢驗分子檢測的標靶治療的發展。

目錄

調查範圍

  • 分析範圍
  • 全球分子診斷應用細分

戰略挑戰

  • 為什麼經濟成長變得越來越困難？
  • The Strategic Imperative 8 TM
  • 工業工程領域三大戰略挑戰的影響

成長機會分析

  • 成長指標
  • 成長促進因素
  • 成長促進因素分析
  • 成長抑制因素
  • 成長抑制因素的分析
  • 推動分子診斷市場擴張的成長要素
  • 重新定義MDx的四項結構性變化
  • 分子診斷技術的融合矩陣
  • 市場趨勢一：對快速診斷的需求不斷成長，加速了分子診斷產業的成長
  • 市場趨勢 2：NGS 的引入擴大了個人化醫療的市場主導。
  • 市場趨勢 3：併購活動正在重塑分子診斷產業的競爭格局。
  • 市場趨勢四：新興技術推動分子診斷領域的競爭差異化
  • 人工智慧副駕駛：透過工作流程自動化提高診斷準確性
  • 支持可擴展分子診斷的數位基礎設施
  • 透過伴隨診斷和與製藥業的合作進行分子診斷
  • 伴隨診斷（CDx）的良性循環
  • 整合精準分子腫瘤治療的連續性
  • 全球分子診斷市場競爭格局
  • 競爭格局：新興企業
  • 分子診斷領域的競爭格局：早期偵測與人工智慧主導平台的競爭
  • 透過診斷和製藥之間的協同效應創造價值
  • 基礎設施的廣泛發展正在推動分子診斷的關鍵趨勢。
  • 當前監管狀況：邁向協調統一的藍圖
  • 分子診斷市場監理趨勢的變化

成長機會整體情況

  • 成長機會 1：人工智慧整合分子診斷平台加速精準醫療和臨床決策支援。
  • 成長機會 2：多體學液態生物檢體平台擴展了早期癌症檢測和微量殘存疾病監測。
  • 成長機會3：NGS技術的擴展，實現全面的基因組分析
  • 成長機會 4：藥物基因體學主導的分子檢測可改善個人化藥物選擇和治療效果。

前景

  • 成長機會的益處和影響
  • 未來發展
  • 圖表清單
簡介目錄
Product Code: PLOQ-55

The molecular diagnostics industry is undergoing consolidation, requiring capital investment and faster regulatory pathways to accelerate clinical adoption. Major diagnostics and life sciences companies are acquiring proprietary testing platforms to strengthen positions in precision oncology and blood-based diagnostics. AI-enabled genomic workflow systems are emerging as key competitive differentiators by enabling large-scale genomic interpretation and improving accessibility of advanced diagnostics in routine care. The convergence of dPCR, NGS, CRISPR-Cas, and nanotechnology is creating multi-platform molecular testing ecosystems with improved speed, accuracy, and scalability across oncology, infectious diseases, and precision medicine. NGS continues to drive adoption through rapid, cost-effective multi-gene analysis for oncology, rare diseases, and reproductive health, with companies such as MGI Tech expanding access through automated sequencing solutions. The sector is also witnessing increased mergers and acquisitions aimed at portfolio expansion, R&D enhancement, and commercialization acceleration. Simultaneously, AI is evolving into a laboratory co-pilot, improving operational efficiency and diagnostic accuracy through integration with LIMS and human-in-the-loop clinical validation frameworks. Companion diagnostics are becoming central to precision medicine, with collaborations between Thermo Fisher and Pfizer, Guardant Health and Pfizer, and Illumina with pharmaceutical companies enabling targeted therapies supported by validated molecular testing.

Table of Contents

Research Scope

  • Scope of Analysis
  • Global Molecular Diagnostics Application Segmentation

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8TM
  • The Impact of the Top 3 Strategic Imperatives on the Industrial Engineering Industry

Growth Opportunity Analysis

  • Growth Metrics
  • Growth Drivers
  • Growth Driver Analysis
  • Growth Restraints
  • Growth Restraint Analysis
  • Growth Drivers Accelerating Molecular Diagnostics Market Expansion
  • Four Structural Shifts Redefining MDx
  • The Molecular Diagnostics Technology Convergence Matrix
  • Market Trend 1: Rising Demand for Rapid Diagnostics Accelerates Growth in the Molecular Diagnostics Industry
  • Market Trend 2: NGS Adoption Expanding Market Leadership in Personalized Medicine
  • Market Trend 3: M&A Momentum Reshaping Competitive Dynamics in the Molecular Diagnostics Industry
  • Market Trend 4: Emerging Technologies Driving Competitive Differentiation in Molecular Diagnostics
  • The Al Co-Pilot: Workflow Automation to Diagnostic Precision
  • The Digital Backbone Powering Scalable Molecular Diagnostics
  • Molecular Diagnostics and Pharma Interlock Through Companion Diagnostics
  • The Companion Diagnostics (CDx) Flywheel
  • Consolidating the Precision Molecular Oncology Care Continuum
  • Global Molecular Diagnostics Competitive Landscape
  • Competitive Landscape: Emerging Players
  • Competitive Landscape of Molecular Diagnostics: Race Toward Early Detection and AI-Led Platforms
  • Unlocking Value Through Diagnostics–Pharma Synergies
  • Broader Infrastructure Moves Support the Core Molecular Trends
  • The Regulatory Reality: A Harmonization Roadmap
  • Changing Regulatory Dynamics in the Molecular Diagnostics Market

Growth Opportunity Universe

  • Growth Opportunity 1: AI-Integrated Molecular Diagnostics Platforms Accelerate Precision Medicine and Clinical Decision Support
  • Growth Opportunity 2: Multiomics Liquid Biopsy Platforms Expand Early Cancer Detection and Minimal Residual Disease Monitoring
  • Growth Opportunity 3: Expansion of NGS Enabling Comprehensive Genomic Profiling
  • Growth Opportunity 4: Pharmacogenomics-Driven Molecular Testing Enhances Personalized Drug Selection and Treatment Outcomes

Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits